Tandem Diabetes Care filings document the company’s insulin delivery business, Nasdaq-listed common stock, operating results, governance matters, and capital structure. Recent 8-K reports furnish quarterly and annual financial results, guidance-related disclosures, and product or regulatory events tied to its diabetes technology portfolio.
The filing record also includes proxy materials for annual meeting voting, director elections, executive compensation, equity awards, and board committee matters. Material-event filings describe the company’s completed 0.00% convertible senior notes offering, related indenture terms, and FDA clearance for the SteadiSet wearable infusion set.
Tandem Diabetes (TNDM) filing under Rule 144 reports an intended sale of 266 shares of Common stock tied to Restricted Stock Units, dated 05/15/2026. The filing also lists prior 10b5-1 sales by Mark Novara of 187 shares on 03/17/2026 and 2 shares on 03/05/2026.
Tandem Diabetes Care EVP & Chief Technology Officer Rick Carpenter reported routine equity compensation activity involving restricted stock units and an employee stock purchase plan. On May 15, 2026, he acquired 1,336 shares of common stock at $10.90 through the company’s employee stock purchase plan and vested RSUs that converted into shares.
To cover tax obligations on these RSU vestings, 4,466 shares were withheld by the company at $12.82 per share, and footnotes clarify that no shares were sold in the market. After all transactions, Carpenter directly held 25,979 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care executive Elizabeth Anne Gasser reported several compensation-related stock transactions dated May 15, 2026. She exercised restricted stock units into a total of 10,267 shares of common stock at a stated price of $0.00 per share and received a separate grant of 1,337 shares at $10.90 per share.
To cover tax obligations on these vestings, the company withheld 5,510 shares at $12.82 per share, and the footnotes state that no shares were sold. After these transactions, she directly holds 1,762 shares of common stock and indirectly holds 25,949 shares through The Gasser Family Trust. A footnote also notes voluntary reporting of an acquisition under the company’s Employee Stock Purchase Plan for a period ending May 15, 2026.
Tandem Diabetes Care EVP & Chief Legal Officer Shannon M. Hansen reported routine equity compensation activity in company stock. On May 15, 2026, she exercised restricted stock units covering a total of 10,201 shares of common stock, and 5,192 shares were withheld by the company to satisfy tax obligations; footnotes state no shares were sold on the market. She also voluntarily reported acquiring 1,886 shares through the company’s Employee Stock Purchase Plan at $10.90 per share. Following these transactions, she directly holds 28,285 shares of common stock and indirectly holds 1,935 shares through the Shannon M. Hansen Trust.
Tandem Diabetes Care EVP & COO Jean-Claude Kyrillos reported routine equity compensation activity involving restricted stock units (RSUs), tax withholding, and an employee stock purchase. On May 15, 2026, 4,038 RSUs converted into common stock and 2,139 shares were withheld to cover taxes, with no shares sold. He also acquired 434 shares through the company’s employee stock purchase plan. Following these transactions, he directly holds 27,671 shares of Tandem Diabetes Care common stock.
Tandem Diabetes Care EVP & Chief Administrative Officer Susan Morrison reported a series of routine equity compensation transactions in company stock. She acquired 9,523 shares of common stock through the vesting and conversion of restricted stock units and 1,336 shares through the employee stock purchase plan at $10.90 per share.
To cover tax obligations on these vestings, 2,724 shares were withheld by the company, and no shares were sold on the open market. After these transactions, Morrison directly holds 43,708 shares of common stock.
Tandem Diabetes Care President and CEO John F. Sheridan reported routine equity compensation activity in common stock. On May 15, 2026, he acquired 1,336 shares at $10.90 per share through the company’s Employee Stock Purchase Plan. Several restricted stock unit awards vested and were exercised into a total of 51,189 shares of common stock. To cover related tax obligations, 24,773 shares were withheld by the company at $12.82 per share, and the footnotes state that no shares were sold on the market.
Tandem Diabetes Care EVP & Chief Financial Officer Leigh Vosseller reported several equity compensation transactions in company stock. On May 15, 2026, she exercised restricted stock units converting a total of 13,495 shares of common stock, and 4,843 shares were withheld by the company to cover tax obligations, with no shares sold. She also acquired 1,336 shares through the company’s Employee Stock Purchase Plan at $10.90 per share. Following these transactions, she directly holds 40,374 shares of common stock and an additional 25,580 shares are held indirectly through the Leigh A. Vosseller Trust.
Tandem Diabetes Care EVP & Chief Commercial Officer Mark David Novara reported routine equity compensation activity. On May 15, 2026, he acquired a total of 10,572 shares of common stock through the vesting and conversion of restricted stock units. To cover tax obligations on these vestings, 7,911 shares were withheld by the company at a reference price of $12.82 per share, and the footnotes state that no shares were sold in the market.
Tandem Diabetes Care, Inc. reported that on May 11, 2026, Executive Vice President and Chief Commercial Officer Mark Novara was notified that his employment is being terminated without cause. His last day with the company is scheduled for May 18, 2026. The company stated that its strategy and 2026 goals remain unchanged.